HomeCompareSUHJY vs ABBV

SUHJY vs ABBV: Dividend Comparison 2026

SUHJY yields 2.63% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $81.7K in total portfolio value
10 years
SUHJY
SUHJY
● Live price
2.63%
Share price
$16.88
Annual div
$0.44
5Y div CAGR
-30%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.7K
Annual income
$7.80
Full SUHJY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SUHJY vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSUHJYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SUHJY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SUHJY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SUHJY
Annual income on $10K today (after 15% tax)
$223.55/yr
After 10yr DRIP, annual income (after tax)
$6.63/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,049.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SUHJY + ABBV for your $10,000?

SUHJY: 50%ABBV: 50%
100% ABBV50/50100% SUHJY
Portfolio after 10yr
$61.5K
Annual income
$12,389.78/yr
Blended yield
20.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SUHJY
No analyst data
Altman Z
2.7
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SUHJY buys
0
ABBV buys
0
No recent congressional trades found for SUHJY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSUHJYABBV
Forward yield2.63%3.06%
Annual dividend / share$0.44$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-30%40.6%
Portfolio after 10y$20.7K$102.3K
Annual income after 10y$7.80$24,771.77
Total dividends collected$609.00$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SUHJY vs ABBV ($10,000, DRIP)

YearSUHJY PortfolioSUHJY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,884$184.10$11,550$430.00$666.00ABBV
2$11,777$131.09$13,472$627.96$1.7KABBV
3$12,694$92.80$15,906$926.08$3.2KABBV
4$13,648$65.44$19,071$1,382.55$5.4KABBV
5$14,650$46.03$23,302$2,095.81$8.7KABBV
6$15,708$32.32$29,150$3,237.93$13.4KABBV
7$16,830$22.67$37,536$5,121.41$20.7KABBV
8$18,024$15.89$50,079$8,338.38$32.1KABBV
9$19,296$11.13$69,753$14,065.80$50.5KABBV
10$20,655$7.80$102,337$24,771.77$81.7KABBV

SUHJY vs ABBV: Complete Analysis 2026

SUHJYStock

Sun Hung Kai Properties Limited develops and invests in properties for sale and rent in Hong Kong, Mainland China, Singapore, and internationally. It develops and sells properties, including residential estates, offices, shopping malls, industrial buildings, and hotels and serviced suites. As of June 30, 2021, the company's land bank comprised 57.9 million square feet of gross floor area in Hong Kong; and 75.3 million square feet of gross floor area in Mainland China. It also provides property management services; construction-related services, including landscaping, electrical and fire prevention systems, and construction plant and machinery leasing; and insurance products to individuals and businesses comprising householder's comprehensive, fire, employees' compensation, travel, personal accident, motor vehicles, contractors' all risks, third party liability, and property all risks. In addition, the company offers voice, multimedia, and mobile broadband services; and data center services, including infrastructure, facility management, server co-location, and other value-added services. Further, it manages car parks, tunnels, bridges, and toll roads; offers transport facilities for private and the public sectors; operates an expressway; provides public bus transportation services; and offers airport freight forwarding and aviation support services. Additionally, the company provides container handling and storage, container freight station, and other port-related services; operates department stores and supermarkets; and offers mortgage and other loan financing facilities, as well as asset and project management, architectural and engineering, cleaning, and secretarial services. It also engages in club and road management activities. The company was formerly known as Sun Hung Kai (Holdings) Limited and changed its name to Sun Hung Kai Properties Limited in March 1973. Sun Hung Kai Properties Limited was incorporated in 1972 and is based in Wan Chai, Hong Kong.

Full SUHJY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SUHJY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SUHJY vs SCHDSUHJY vs JEPISUHJY vs OSUHJY vs KOSUHJY vs MAINSUHJY vs JNJSUHJY vs MRKSUHJY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.